Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Symic Biomedical advances SB-030 into clinical development

Oct. 28, 2015

Mast Therapeutics begins phase II study of vepoloxamer for chronic heart failure

Oct. 27, 2015

GSK receives CHMP positive opinion to expand indication for Volibris

Oct. 26, 2015

Theravance submits IND for neprilysin inhibitor TD-0714

Oct. 15, 2015

MyoKardia provides update on two phase I trials of MYK-461

Oct. 8, 2015

Chungnam National University introduces cardiac myosin activators

Oct. 7, 2015

Cell Therapy plans European CMA submission for Heartcel

Oct. 6, 2015

Gilead's new treatment combination of Letairis and tadalafil gains FDA approval for PAH

Oct. 6, 2015

FDA accepts Jazz Pharmaceuticals' NDA for defibrotide in hepatic veno-occlusive disease

Oct. 5, 2015

Bayer presents new soluble guanylate cyclase activators

Oct. 2, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...